DRTS heads into today's earnings print having gained 22% in a single week — while nearly every comparable medical device name fell sharply.
That outperformance stands out. The stock closed at $10.36 on May 15, up 32% over the past month, powered by momentum from Alpha DaRT's 81% disease control rate in pancreatic cancer trials and the company's FDA pre-market approval submission for recurrent cutaneous squamous cell carcinoma. In a week where Nasdaq-listed peers BWAY dropped 34% and LIVN fell 24%, DRTS moved in the opposite direction. That kind of divergence points to buying specific to the clinical story, not broad sector rotation.
The borrow market tells its own story. Cost to borrow has climbed to 10.8%, up roughly 54% over the past month — a meaningful increase for a stock of this size. Availability has swung wildly. It touched 18% earlier in the week before recovering to around 39%, compared to a 52-week low of just 2.2%. That volatility suggests the lending pool is being actively used and is sensitive to short-term positioning shifts. Short interest itself remains modest at 1.4% of the free float — doubling over the past month in share count, but starting from a low base. The short score of 56.6 is middling. This is not a heavily shorted name, but borrow conditions have clearly tightened alongside the rally.
Options traders are positioned decidedly bullishly. The put/call ratio has collapsed to 0.11, nearly 1.6 standard deviations below its 20-day average of 0.16 — meaning call demand has swamped put demand heading into the print. That's a notable shift from mid-April, when the PCR was running above 0.20. The move from defensive to aggressively bullish options positioning mirrors the price action: investors are leaning into the rally, not hedging it.
The analyst debate comes down to a simple question of durability. Two firms — Ladenburg Thalmann and HC Wainwright — raised targets to $14 and $15 respectively on May 12, both maintaining Buy ratings. With the stock now at $10.36, those targets imply meaningful upside. The bull case centres on the FDA submission, Alpha DaRT's breakthrough device designation, and the upcoming New Hampshire manufacturing facility, which should expand capacity in 2026. Bears focus on the balance sheet: the company burned through roughly $26 million in operating cash flow last year on revenues of just $1.7 million, and the cash position will need replenishing to fund ongoing trials. Piper Sandler downgraded to Neutral back in March with a $5 target — well below the current price — though the stock has since run far past that level.
Past earnings prints have consistently produced upside. After the four most recent events, the stock moved between 4% and 7% higher on day one, with the five-day window adding 7% to 14% on average. The earnings report today will test whether clinical progress translates into any clearer path to commercialisation — and whether that's enough to justify a stock trading well above the most cautious analyst on the Street.
See the live data behind this article on ORTEX.
Open DRTS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
